Klaria Releases Corrected Q2 2026 Interim Report
Klaria has released a corrected version of its interim report for the second quarter of 2026. The report covers the period from April 1 to June 30, 2026.
Pharmaceutical company Klaria has issued a corrected version of its interim report for the second quarter of 2026, covering the period from April 1 to June 30, 2026.
The total group reported net sales of 0.0 MSEK, unchanged from the same period in the previous year. Other income also remained at 0.0 MSEK.
Research and development expenses decreased significantly in the second quarter, amounting to 4.4 MSEK, compared to 7.1 MSEK in the prior year. Profit after tax improved to -12.9 MSEK from -20.1 MSEK in the corresponding period last year. Earnings per share for the quarter were -0.05 SEK.
Cash flow from operating activities was -14.8 MSEK, a decrease from -2.3 MSEK in the previous year. Liquid assets at the end of the reporting period stood at 8.5 MSEK, a substantial increase from 2.0 MSEK a year prior. The group's equity at the balance sheet date is also detailed in the report.